Search

Displaying results 8191 - 8200 of 10000 in total
  1. Drug

    Adermastat

    go.drugbank.com/drugs/DB28906
    Investigational

    Adermastat is a small molecule drug.

  2. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  3. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is a biologic drug. MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  4. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.

  5. Drug

    FRAX716

    go.drugbank.com/drugs/DB31795
    Experimental

    FRAX716 is a group I-specific p21-activated kinase (PAK) inhibitor which dramatically inhibits the phosphorylation of PAK and Mek1.[A274678]

  6. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    PHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production.

  7. Drug

    Zamubafusp alfa

    go.drugbank.com/drugs/DB32269
    Investigational

    [L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]

  8. Drug

    YMI024

    go.drugbank.com/drugs/DB32602
    Experimental

    YMI024 is a drug being investigated for inflammation-driven diseases.[L56081]

  9. Drug

    SI-109

    go.drugbank.com/drugs/DB32603
    Experimental

    SI-109 is a potent, small-molecule inhibitor of the STAT3 SH2 domain.[A275443]

  10. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]